The absence of any hantavirus vaccine candidate that has advanced beyond early-stage or preclinical testing drives the 94.5% market-implied probability against approval or licensure by the end of 2026. Authoritative sources confirm no Phase 3 trials are underway for Andes virus or related orthohantaviruses, with candidates such as mRNA constructs from Moderna-Korea University partnerships and DNA-based platforms limited to animal immunogenicity data or small Phase 1 safety studies as of mid-2026. A May 2026 cruise-ship outbreak and associated CDC/WHO alerts underscored the clinical need but also highlighted that standard vaccine development and regulatory timelines—typically requiring multi-year efficacy trials—preclude resolution this year. Realistic challenges to the consensus would require an unanticipated emergency-use authorization pathway or accelerated approval based on surrogate endpoints, though historical precedent for such rare pathogens shows these remain improbable without completed late-stage data.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$129,600 Vol.
$129,600 Vol.
Dec 31, 2026
6% chance
$129,600 Vol.
$129,600 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any hantavirus vaccine candidate that has advanced beyond early-stage or preclinical testing drives the 94.5% market-implied probability against approval or licensure by the end of 2026. Authoritative sources confirm no Phase 3 trials are underway for Andes virus or related orthohantaviruses, with candidates such as mRNA constructs from Moderna-Korea University partnerships and DNA-based platforms limited to animal immunogenicity data or small Phase 1 safety studies as of mid-2026. A May 2026 cruise-ship outbreak and associated CDC/WHO alerts underscored the clinical need but also highlighted that standard vaccine development and regulatory timelines—typically requiring multi-year efficacy trials—preclude resolution this year. Realistic challenges to the consensus would require an unanticipated emergency-use authorization pathway or accelerated approval based on surrogate endpoints, though historical precedent for such rare pathogens shows these remain improbable without completed late-stage data.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$129,600End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any hantavirus vaccine candidate that has advanced beyond early-stage or preclinical testing drives the 94.5% market-implied probability against approval or licensure by the end of 2026. Authoritative sources confirm no Phase 3 trials are underway for Andes virus or related orthohantaviruses, with candidates such as mRNA constructs from Moderna-Korea University partnerships and DNA-based platforms limited to animal immunogenicity data or small Phase 1 safety studies as of mid-2026. A May 2026 cruise-ship outbreak and associated CDC/WHO alerts underscored the clinical need but also highlighted that standard vaccine development and regulatory timelines—typically requiring multi-year efficacy trials—preclude resolution this year. Realistic challenges to the consensus would require an unanticipated emergency-use authorization pathway or accelerated approval based on surrogate endpoints, though historical precedent for such rare pathogens shows these remain improbable without completed late-stage data.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$129,600End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The absence of any hantavirus vaccine candidate that has advanced beyond early-stage or preclinical testing drives the 94.5% market-implied probability against approval or licensure by the end of 2026. Authoritative sources confirm no Phase 3 trials are underway for Andes virus or related orthohantaviruses, with candidates such as mRNA constructs from Moderna-Korea University partnerships and DNA-based platforms limited to animal immunogenicity data or small Phase 1 safety studies as of mid-2026. A May 2026 cruise-ship outbreak and associated CDC/WHO alerts underscored the clinical need but also highlighted that standard vaccine development and regulatory timelines—typically requiring multi-year efficacy trials—preclude resolution this year. Realistic challenges to the consensus would require an unanticipated emergency-use authorization pathway or accelerated approval based on surrogate endpoints, though historical precedent for such rare pathogens shows these remain improbable without completed late-stage data.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions